Catalyst Pharmaceuticals Company Insiders
CPRX Stock | USD 20.55 0.02 0.1% |
Catalyst Pharmaceuticals employs about 181 people. The company is managed by 16 executives with a total tenure of roughly 33 years, averaging almost 2.0 years of service per executive, having 11.31 employees per reported executive. Break down of Catalyst Pharmaceuticals' management performance can provide insight into the company performance.
Patrick McEnany Chairman Co-Founder, Chairman, CEO and Pres |
Catalyst Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.1813 % which means that it generated a profit of $0.1813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2849 %, meaning that it created $0.2849 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Catalyst Pharmaceuticals Workforce Comparison
Catalyst Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 4,780. Catalyst Pharmaceuticals holds roughly 181 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.37 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45. Catalyst Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Catalyst Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gregg Russo over a week ago Insider Trading | ||
Tierney David S over a month ago Disposition of 1333 shares by Tierney David S of Catalyst Pharmaceuticals subject to Rule 16b-3 | ||
Elsbernd Brian over a month ago Disposition of 30000 shares by Elsbernd Brian of Catalyst Pharmaceuticals at 20.3 subject to Rule 16b-3 | ||
Miller Steve over a month ago Acquisition by Miller Steve of 110000 shares of Catalyst Pharmaceuticals at 2.24 subject to Rule 16b-3 | ||
Patrick McEnany over three months ago Disposition of 171748 shares by Patrick McEnany of Catalyst Pharmaceuticals at 26.11 subject to Rule 16b-3 | ||
Ingenito Gary over three months ago Disposition of 44000 shares by Ingenito Gary of Catalyst Pharmaceuticals at 23.63 subject to Rule 16b-3 | ||
Miller Steve over three months ago Disposition of 14000 shares by Miller Steve of Catalyst Pharmaceuticals subject to Rule 16b-3 | ||
Ingenito Gary over three months ago Disposition of 200000 shares by Ingenito Gary of Catalyst Pharmaceuticals at 23.68 subject to Rule 16b-3 |
Catalyst Pharmaceuticals Notable Stakeholders
A Catalyst Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Catalyst Pharmaceuticals often face trade-offs trying to please all of them. Catalyst Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Catalyst Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Richard MBA | CEO President | Profile | |
Patrick McEnany | Co-Founder, Chairman, CEO and Pres | Profile | |
Michael CPA | Executive CFO | Profile | |
Steven Miller | COO and Chief Scientific Officer | Profile | |
Philip Schwartz | Co Sec | Profile | |
CMA CPA | VP, Officer | Profile | |
Pete Sr | Vice Sales | Profile | |
Mary Coleman | VP Relations | Profile | |
Stanley MD | Senior Discovery | Profile | |
Philip Esq | Corporate Secretary | Profile | |
Gary MD | Chief Officer | Profile | |
Jeffrey Carmen | Executive Officer | Profile | |
Preethi Sundaram | Chief Officer | Profile | |
Gregg Russo | Chief Officer | Profile | |
MD FACP | Chief Officer | Profile | |
Brian JD | Chief Officer | Profile |
About Catalyst Pharmaceuticals Management Performance
The success or failure of an entity such as Catalyst Pharmaceuticals often depends on how effective the management is. Catalyst Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Catalyst management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Catalyst management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people.
Please note, the imprecision that can be found in Catalyst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Catalyst Pharmaceuticals. Check Catalyst Pharmaceuticals' Beneish M Score to see the likelihood of Catalyst Pharmaceuticals' management manipulating its earnings.
Catalyst Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Catalyst Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Catalyst Pharmaceuticals within its industry.Catalyst Pharmaceuticals Manpower Efficiency
Return on Catalyst Pharmaceuticals Manpower
Revenue Per Employee | 2.7M | |
Revenue Per Executive | 30.7M | |
Net Income Per Employee | 905.5K | |
Net Income Per Executive | 10.2M | |
Working Capital Per Employee | 2.8M | |
Working Capital Per Executive | 31.4M |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.